Transfusion-transmitted cytomegalovirus infection

Abstract

Transfusion-associated cytomegalovirus (CMV) infections is associated with significant morbidity and mortality in immunocompromised seronegative patients. Seronegative blood products reduce the incidence of infection to less than 7%. Filtered blood may be an effective alternative to seronegative blood products for prevention of transfusion-associated CMV infection. The clinical significance of second strain CMV infection remains undefined.